OTC Acne Treatment Labels Should Add Sensitivity Test Direction – FDA
This article was originally published in The Tan Sheet
Executive Summary
OTC topical acne drug product manufacturers have an option to add label directions for sensitivity testing for new users of their products, “to reduce the risk of serious hypersensitivity reactions,” the FDA says.
You may also be interested in...
FDA Evaluates Topical Acne Ingredients After Adverse Event Report Jump
A recent uptick in the number of adverse events reported for benzoyl peroxide and salicylic acid products has pushed the regulatory agency to take a closer look at the potential for safety issues.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.